Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations

Miscellaneous

This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that have spread to other places in the body (metastatic) and usually cannot be cured or controlled with treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Miscellaneous
II
Davis, Elizabeth
NCT03212274
VICCMD18129ET-CT

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Neuro-Oncology

Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. Approximately 340 participants are planned to be randomized 1:1 to receive orally administered vorasidenib 40 mg QD or placebo.
Neuro-Oncology
III
Moots, Paul
NCT04164901
VICCNEU2015

Testing Atezolizumab and Bevacizumab in People with Advanced Alveolar Soft Part Sarcoma

Sarcoma

This phase II trial studies how well atezolizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body (advanced) and cannot be removed by surgery (unresectable). Atezolizumab works by unblocking the immune system, allowing the immune system cells to recognize and then attack tumor cells. Bevacizumab works by controlling the growth of new blood vessels. Giving atezolizumab and bevacizumab may shrink the cancer.
Sarcoma
II
Davis, Elizabeth
NCT03141684
VICCSAR16155ET-CT

A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

Hematologic

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine if CAEL-101 improves the overall survival in Patients with cardiac AL Amyloidosis.
Hematologic
III
Sengsayadeth, Salyka
NCT04512235
VICCPCL2080

Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository

Multiple Cancer Types

Dermatologic, Melanoma
N/A
Kauffmann, Rondi
VICCMEL0287

Repository for National Donor Program (NMDP) Research Blood Samples.

Hematologic

Hematologic
N/A
Kassim, Adetola
NMDPCTT0346

Donating Tissues for Research

Miscellaneous

Miscellaneous
N/A
Washington, Mary Kay
VICCBIO0478

REACH (Research, Education, Advocacy, Clinical Care and Health) for Survivorship Program: Long Term Effects for Survivors of Cancer

Multiple Cancer Types

Miscellaneous, Pediatrics
N/A
Esbenshade, Adam
VICCPED0710

Severe Chronic Neutropenia International Registry

Benign Hematologic

Benign Hematologic
N/A
McDaniel, Heather
VICCNCPED10104

Hematologic Malignancy Tumor Bank

Multiple Cancer Types

Hematologic, Leukemia, Lymphoma
N/A
Seegmiller, Adam
VICCHEM1217

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: